Get startedLog in
    Picture of Regeneron Pharmaceuticals logo

    REGN — Regeneron Pharmaceuticals Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Regeneron Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:10-K10-K10-K10-K10-K
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line8,0754,3383,9544,4134,505
    Depreciation
    Deferred Taxes
    Non-Cash Items7831,3251,151901183
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-1,917-243-94.1-618533
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Cash from Operating Activities7,0815,0154,5944,4214,979
    Capital Expenditures-552-1,617-926-882-1,214
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-4,833-2,168-2,259-1,587585
    Acquisition of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Purchase of Investments
    Cash from Investing Activities-5,385-3,785-3,185-2,468-629
    Financing Cash Flow Items-1,033-446-701-1,063-542
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-1,006-1,009-1,790-2,201-3,715
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash691221-382-249635